Pfizer Spent $43 Billion to Become an Oncology Leader. So Why Do Its MSLs Rank Last With Oncologists?

Microscope and research notes in a laboratory overlooking a city skyline

Pfizer currently has one of the weakest signals in oncology physician engagement. Pfizer spent $43 billion to acquire Seagen and transform itself into an oncology powerhouse—yet its oncology MSL organization subsequently ranked dead last among 20 manufacturers in a physician survey.

ZoomRx’s 2026 Oncology Medical Engagement Perception Report is based on 51 U.S. academic and community oncology specialists who had recently interacted with MSL teams. Among 20 manufacturers, Pfizer stands out as the poorest-rated team.

ZoomRx’s 2026 Oncology Medical Engagement Perception Report surveyed 51 U.S. academic and community oncology specialists who had interacted with MSLs during the prior three months. Physicians evaluated teams on scientific depth, responsiveness, communication, research collaboration, objectivity/trust, practice relevance, and material quality. (ZoomRx)

RankPharmaMSL Performance
1Roche/Genentech80%
2AstraZeneca79%
3Bayer77%
4AbbVie72%
5Amgen70%
9Bristol Myers Squibb64%
10Merck64%
12Eli Lilly61%
15Novartis57%
16Jazz53%
17GSK53%
18Takeda51%
19Sanofi42%
20Pfizer31%

The Pfizer result is striking. It wasn’t merely last—it was 11 percentage points behind Sanofi and 49 points behind Roche/Genentech. Pfizer’s MSL reach was also only 20% of the surveyed oncologists. (ZoomRx)

More important than the number is why oncologists marked Pfizer down. Respondents cited inadequate responsiveness around investigator-initiated studies and interactions that weren’t sufficiently personalized to their clinics’ needs. Sanofi had a different problem: physicians described insufficiently detailed interactions and lack of continuity, including repeatedly dealing with someone new. (ZoomRx)

A very strong blog is hiding in these numbers.

Pfizer spent $43 billion to acquire Seagen and build a much larger oncology position, yet its MSL organization ranks #20 out of 20 in this survey. And there’s an intriguing historical angle: an earlier ZoomRx analysis had Pfizer ranked #4 among oncology companies for MSL guidance. (Blog)

That doesn’t prove the Seagen acquisition caused the decline—the studies aren’t necessarily methodologically comparable, and the 2026 sample is only 51 oncologists. But it gives us a legitimate question to investigate:

Did Pfizer’s transformation into a bigger oncology company actually weaken the physician relationships that are supposed to make that portfolio successful? That could be an even stronger article than the BMS/Celgene piece because we have a concrete #20 ranking and a 31% MSL performance score as the hook.

Low-rated MSLs can hurt a pharma brand far beyond the medical affairs department. Because MSLs are often the company’s scientific face, poor interactions can translate into weaker trust in the brand itself.

The main consequences are lower scientific credibility, weaker KOL relationships, reduced physician engagement, poorer insight collection, less enthusiasm for new clinical data, and potentially slower adoption after launch. It can also make investigators less interested in research collaboration and give competitors with stronger medical teams a greater share of voice.

A pharma company can spend billions developing or acquiring a drug, but if its MSLs don’t earn physicians’ trust, much of that investment can be commercially handicapped.

MSLs aren’t supposed to sell the brand—but the quality of their scientific engagement can strongly influence the environment in which the brand succeeds or fails.

A move away from science?

The concern that there is a move away from science and towards commercial leads to significant tension in Medical Affairs. As companies demand more measurable “impact” from MSL organizations, scientific exchange risks looking increasingly like another form of commercial engagement.

MSLs are most valuable when physicians view them as credible, objective scientific resources—not sales representatives with advanced degrees. When brand teams exert too much influence over MSL priorities, targeting, messaging, or performance metrics, several things can happen: MSLs may feel pressured to emphasize brand-relevant topics rather than genuine scientific exchange; physicians can become more skeptical about their objectivity; and Medical Affairs can gradually lose the independence that differentiates it from Commercial.

The paradox matters: the harder a pharma company tries to make MSLs commercially productive, the more it risks destroying the credibility that makes MSLs valuable to the brand.

“When an MSL conversation begins to sound like a sales call, Medical Affairs has already lost something far more valuable than a prescription: scientific credibility.”

The fundamental problem is that MSL value comes from something Commercial cannot easily replicate: scientific credibility and perceived independence. When Medical Affairs is increasingly measured against brand priorities, HCP targeting, engagement frequency, launch readiness, competitive positioning, and other commercially adjacent KPIs, MSLs can find themselves caught between two mandates: be an objective scientific partner and demonstrate measurable value to the brand.

That creates a dangerous feedback loop. Brand teams want greater MSL “impact,” so organizations increase targeting and measurement. MSL interactions become more tightly aligned with strategic objectives. Physicians perceive conversations as less organic or less scientifically useful. Engagement quality declines. Management responds by demanding still more measurable activity.

The result can be more MSL activity but less MSL influence.

And there is an important brand consequence. Physicians don’t necessarily separate every interaction into neat corporate silos. If an oncologist concludes that an MSL is essentially delivering a sophisticated version of the company’s commercial narrative, trust can migrate from the MSL to the entire manufacturer—and eventually to the brand.

The greatest threat to the MSL model may not be poor MSL performance. It may be pharma companies redefining “good performance” in commercial terms.

MSLs are scientific representatives of your brand, not to push commercial strategies. Metrics push quantitative rather than qualitative interactions. This explains why MSL leaders with years of experience are being passed over for jobs while hiring people who will only do what they are instructed to do.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply